An initiative of the World Peptide Foundation · Every experience matters
Loading the peptide directory…
Octreotide — Peptide Scientific Intelligence
Scientific intelligence record
Experience 2.0
Somatostatin analog
Octreotide
Octreotide is a synthetic cyclic octapeptide analog of somatostatin with greater metabolic stability and longer action than endogenous somatostatin. It binds predominantly somatostatin receptor subtypes 2 and 5, suppressing growth hormone and several gastroenteropancreatic hormones and secretions; effects therefore vary by receptor expression, disease, route, and formulation. Immediate-release injection, depot injection, and delayed-release oral products have distinct pharmacokinetics and regulatory labeling.
Record status
Traceability partial
Last meaningful update: 9/9/2026
Evidence searched through:
Not recorded
Assessment updated:
9/9/2026
Last human review:
No accountable human review represented
Governed reviewed evidence
25
Governed records, not an efficacy score or total literature count.
Evidence boundary
0 / 25
Claim-linked support versus recorded evidence.
Research gaps
1
Unresolved questions remain visible.
Human experience · separate evidence stream
No community pattern is displayed yet
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
Research chronology
1992 · study · Temporal status not established
Octreotide treatment of acromegaly. A randomized, multicenter study.
Annals of internal medicine
1995 · study · Temporal status not established
The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.
The Journal of clinical endocrinology and metabolism
1997 · study · Temporal status not established
A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis.
International journal of pancreatology : official journal of the International Association of Pancreatology
1999 · study · Temporal status not established
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Connections
Follow the scientific relationships
Connections appear only when they are represented by the project’s underlying records.
Open 12 represented connections ↓Close represented connections ↑
institution
The Journal of clinical endocrinology and metabolism
represented evidence source
institution
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
represented evidence source
institution
Hepato-gastroenterology
represented evidence source
Traceability
Follow the record back to its source
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Claim → Evidence
Incomplete
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Incomplete links: claim-to-evidence
Inspect 25 source paths ↓Close source paths ↑
Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.
Observational archive
What contributors reported
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Reviewed jurisdictional records
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Read the scientific record with its boundaries intact
The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Octreotide evidence · ranking key
How evidence is ranked
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
A
Practice-defining evidence
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
D
Signal-generating evidence
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
Tier and confidence answer different questions
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Governed scientific evidence
Evidence Passport
Duplicate-safe scientific sources under accountable human review. Identified or pending records do not contribute as approved evidence.
0
Insufficient
WPF-EMM-1.0
Identified sources
6
Governed reviewed
0
Evidence approved for publication
0
Audit view
Evidence integrity map
Human and preclinical evidence remain separate. Source identity, claim-to-source traceability, review dates, conflicts, limitations, and unknowns stay visible rather than being collapsed into one score.
4 unresolved signals
Human evidence
0
Preclinical evidence
0
Human experience
Below display gate
Observations never become clinical evidence.
• Gallstones and biliary complications, glucose dysregulation, gastrointestinal effects, bradycardia and conduction changes, thyroid alterations, nutritional effects, injection-site problems, and drug interactions require clinical context. Tumor receptor profile, secretory status, prior response, hepatic function, route, formulation, and administration timing affect benefit and exposure. Small trials, post hoc analyses, surrogate endpoints, and heterogeneous off-label populations limit generalization. Current product labeling—not this profile—controls indications, contraindications, preparation, monitoring, and use.
• The presence of published evidence does not by itself establish safety, efficacy, causation or clinical benefit.
Inspect the published evidence record25 governed records · titles, provenance, and original-source linksOpen records ↓Close records ↑
2021Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.
Results are presented from 2 to 3 trials investigating oral octreotide capsules (OOC) as an alternative to injectable somatostatin receptor ligands (iSRLs) in the treatment of acromegaly.
Authors
Artak Labadzhyan, L B Nachtigall, M Fleseriu, M B Gordon, M Molitch, L Kennedy, S L Samson, Y Greenman, N Biermasz, M Bolanowski, A Haviv, W Ludlam
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs).
Authors
Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker, Jan Harder, Christian Arnold
Source
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DOI
2013Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly.
Acromegaly is caused by excessive GH secretion and IGF-I overproduction.
Authors
Carla Chieffo, David Cook, Qinfang Xiang, Lawrence A Frohman
Source
The Journal of clinical endocrinology and metabolism
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.
Octreotide is a first-generation somatostatin receptor ligand (SRL) approved for acromegaly treatment.
Authors
Anaïs Glatard, Sofia Friberg-Hietala, Lina Keutzer, Anna Hansson, Markus Johnsson, Fredrik Tiberg
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
Somatostatin analogues (SSA) have demonstrated antiproliferative activity in addition to efficacy for carcinoid symptom control in functional neuroendocrine tumors (NET).
Authors
Jonathan R Strosberg, James C Yao, Emilio Bajetta, Mounir Aout, Bert Bakker, John D Hainsworth, Philippe B Ruszniewski, Eric Van Cutsem, Kjell Öberg, Marianne E Pavel
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.
Pharmacological prevention of postoperative pancreatic fistula (POPF) after pancreatectomy is open to debate.
Authors
Sébastien Gaujoux, Jean-Marc Regimbeau, Guillaume Piessen, Stéphanie Truant, Frantz Foissac, Louise Barbier, Emmanuel Buc, Mustapha Adham, David Fuks, Sophie Deguelte, Fabrice Muscari, Laurent Sulpice
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Hepatorenal syndrome (HRS), a serious complication of cirrhosis, is associated with high mortality without treatment.
Authors
Marta Cavallin, Patrick S Kamath, Manuela Merli, Silvano Fasolato, Pierluigi Toniutto, Francesco Salerno, Mauro Bernardi, Roberto Giulio Romanelli, Cosimo Colletta, Freddy Salinas, Antonio Di Giacomo, Lorenzo Ridola
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
70/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
There are no proven, effective therapies for polycystic kidney disease (PKD) or polycystic liver disease (PLD).
Authors
Marie C Hogan, Tetyana V Masyuk, Linda J Page, Vickie J Kubly, Eric J Bergstralh, Xujian Li, Bohyun Kim, Bernard F King, James Glockner, David R Holmes, Sandro Rossetti, Peter C Harris
Source
Journal of the American Society of Nephrology : JASN
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.
No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD).
Authors
Anna Caroli, Luca Antiga, Mariateresa Cafaro, Giorgio Fasolini, Andrea Remuzzi, Giuseppe Remuzzi, Piero Ruggenenti
Source
Clinical journal of the American Society of Nephrology : CJASN
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial.
Acute kidney injury and early allograft dysfunction are 2 common complications after liver transplant.
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Octreotide improves human lymphatic fluid transport a translational trial.
Chylothorax is a complex condition and many different pharmacological agents have been tried as treatment.
Authors
Thomas Holm-Weber, Frederik Skov, Sheyanth Mohanakumar, Lene Thorup, Troels Riis, Mikkel Bring Christensen, David Peick Sonne, Per Bo Jensen, Donna Briggs Bødtkjer, Vibeke Elisabeth Hjortdal
Source
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.
Treatment of acromegaly with intermittent sc injections of octreotide is associated with an increased incidence of cholelithiasis.
Authors
J P Tauber, M F Poncet, A G Harris, H R Barthel, C Simonetta-Chateauneuf, L Buscail, F Bayard
Source
The Journal of clinical endocrinology and metabolism
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.
Despite a strong rationale for trials of somatostatin analogs in the treatment of Graves' ophthalmopathy (GO), recent studies have provided conflicting results.
Authors
Marius N Stan, James A Garrity, Elizabeth A Bradley, John J Woog, Mark M Bahn, Michael D Brennan, Sandra C Bryant, Sara J Achenbach, Rebecca S Bahn
Source
The Journal of clinical endocrinology and metabolism
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
Does octreotide reduce vomiting in cancer-associated bowel obstruction?
Authors
David C Currow, Stephen Quinn, Meera Agar, Belinda Fazekas, Janet Hardy, Nikki McCaffrey, Simon Eckermann, Amy P Abernethy, Katherine Clark
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis.
In this study, octreotide was not found to be of benefit in the treatment of acute pancreatitis.
Authors
C McKay, J Baxter, C Imrie
Source
International journal of pancreatology : official journal of the International Association of Pancreatology
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Randomized controlled trial comparing somatostatin with octreotide in the prevention of complications after pancreatectomy.
The postoperative morbidity following pancreaticoduodenectomy (PD) remains very high.
Authors
Jean Closset, Stephane Journe, Freddy Mboti, Issam El Nakadi, Michel Gelin
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Octreotide in acute bleeding esophageal varices: a prospective randomized study.
To assess the value of octreotide in the control of acute bleeding esophageal varices, in a prospective randomized study.
Authors
D S Freitas, C Sofia, J M Pontes, C Gregório, J P Cabral, P Andrade, A Rosa, E Camacho, M Ferreira, F Portela, J M Romãozinho, L Tomé
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
The aim of this randomized controlled study was to determine whether octreotide (OCT) or scopolamine butylbromide (SB) was the more effective antisecretive drug controlling gastrointestinal (GI) symptoms due to malignant bowel obstruction (MBO) caused by advanced ovarian cancer.
Authors
Xingang Peng, Peige Wang, Shikuan Li, Guangyong Zhang, Sanyuan Hu
Source
World journal of surgical oncology
DOI
10.1186/s12957-015-0455-3
PubMed
2011Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Treatment with somatostatin analogues is the primary medical treatment of acromegaly.
Authors
Sven M Carlsen, Johan Svartberg, Thomas Schreiner, Sylvi Aanderud, Oivind Johannesen, Svein Skeie, Morten Lund-Johansen, Stine L Fougner, Jens Bollerslev, POTA study group
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.
The effect of octreotide plus interferon-alpha versus octreotide monotherapy on the primary study end points of time to treatment failure (progression, death, stop of study treatment) and long-term survival was investigated in patients with progressive metastatic neuroendocrine foregut (mainly pancreatic) and midgut tumors.
Authors
Rudolf Arnold, Anja Rinke, Klaus-Jochen Klose, Hans-Helge Müller, Matthias Wied, Karin Zamzow, Christina Schmidt, Carmen Schade-Brittinger, Peter Barth, Roland Moll, Michael Koller, Michael Unterhalt
Source
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2017Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.
Somatostatin analogs have been shown to control the growth of well-differentiated metastatic neuroendocrine tumors.
Authors
Anja Rinke, Michael Wittenberg, Carmen Schade-Brittinger, Behnaz Aminossadati, Erdmuthe Ronicke, Thomas M Gress, Hans-Helge Müller, Rudolf Arnold, PROMID Study Group
Source
Neuroendocrinology
DOI
10.1159/000443612
PubMed
26731483
1999Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily.
Authors
J Rubin, J Ajani, W Schirmer, A P Venook, R Bukowski, R Pommier, L Saltz, P Dandona, L Anthony
Source
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Octreotide treatment of acromegaly. A randomized, multicenter study.
To determine the effects of the somatostatin analog, octreotide acetate, in patients with acromegaly.
Authors
S Ezzat, P J Snyder, W F Young, L D Boyajy, C Newman, A Klibanski, M E Molitch, A E Boyd, L Sheeler, D M Cook
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial.
Gastrointestinal angiodysplasias are vascular anomalies that may result in transfusion-dependent anemia despite endoscopic therapy.
Authors
Lia C M J Goltstein, Karina V Grooteman, Lucas H P Bernts, Robert C H Scheffer, Robert J F Laheij, Lennard P L Gilissen, Ruud W M Schrauwen, Nynke C Talstra, Abraham T Zuur, Henri Braat, Muhammed Hadithi, Johannes T Brouwer
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Octreotide for congenital and acquired chylothorax in newborns: A systematic review.
Chylothorax is a rare but life-threatening condition in newborns.
Authors
Carlo Bellini, Rita Cabano, Laura C De Angelis, Tommaso Bellini, Maria G Calevo, Paolo Gandullia, Luca A Ramenghi
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
2000 · study · Temporal status not established
Octreotide in acute bleeding esophageal varices: a prospective randomized study.
Hepato-gastroenterology
2005 · study · Temporal status not established
Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2006 · study · Temporal status not established
Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.
The Journal of clinical endocrinology and metabolism
2008 · study · Temporal status not established
Randomized controlled trial comparing somatostatin with octreotide in the prevention of complications after pancreatectomy.
Hepato-gastroenterology
2009 · study · Temporal status not established
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010 · study · Temporal status not established
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
Journal of the American Society of Nephrology : JASN
2010 · study · Temporal status not established
Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.
Clinical journal of the American Society of Nephrology : CJASN
2011 · study · Temporal status not established
Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Clinical endocrinology
2013 · study · Temporal status not established
Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly.
The Journal of clinical endocrinology and metabolism
2015 · study · Temporal status not established
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
Endocrine-related cancer
2015 · study · Temporal status not established
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Hepatology (Baltimore, Md.)
2015 · study · Temporal status not established
Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
Journal of pain and symptom management
2015 · study · Temporal status not established
Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
World journal of surgical oncology
2017 · study · Temporal status not established
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.
Neuroendocrinology
2018 · study · Temporal status not established
Octreotide for congenital and acquired chylothorax in newborns: A systematic review.
Journal of paediatrics and child health
2021 · study · Temporal status not established
Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.
Pituitary
2022 · study · Temporal status not established
Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
2024 · study · Temporal status not established
Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.
Annals of surgery
2024 · study · Temporal status not established
Octreotide improves human lymphatic fluid transport a translational trial.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
2024 · study · Temporal status not established
Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial.
Gastroenterology
2025 · study · Temporal status not established
Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.
Clinical pharmacokinetics
2026 · regulatory · Temporal status not established
Regulatory review: approved
United States (FDA — MYCAPSSA)
2026 · regulatory · Temporal status not established
Regulatory review: approved
United States (FDA — SANDOSTATIN LAR DEPOT)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
What still needs investigation
Claim traceability
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
Researchers represented in the evidence record12 bibliographic identities · open to inspect
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
Anja Rinke
3 represented evidence records
Years represented: 2005, 2009, 2017
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology
Carmen Schade-Brittinger
3 represented evidence records
Years represented: 2005, 2009, 2017
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology
Hans-Helge Müller
3 represented evidence records
Years represented: 2005, 2009, 2017
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology
Behnaz Aminossadati
2 represented evidence records
Years represented: 2009, 2017
Publishing organizations appearing in records: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology
Klaus-Jochen Klose
2 represented evidence records
Years represented: 2005, 2009
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Matthias Wied
2 represented evidence records
Years represented: 2005, 2009
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Peter Barth
2 represented evidence records
Years represented: 2005, 2009
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Rudolf Arnold
2 represented evidence records
Years represented: 2005, 2017
Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Neuroendocrinology
A E Boyd
1 represented evidence record
Years represented: 1992
Publishing organizations appearing in records: Annals of internal medicine
A G Harris
1 represented evidence record
Years represented: 1995
Publishing organizations appearing in records: The Journal of clinical endocrinology and metabolism
A Haviv
1 represented evidence record
Years represented: 2021
Publishing organizations appearing in records: Pituitary
A Klibanski
1 represented evidence record
Years represented: 1992
Publishing organizations appearing in records: Annals of internal medicine
institution
Pituitary
represented evidence source
institution
Clinical pharmacokinetics
represented evidence source
institution
Endocrine-related cancer
represented evidence source
institution
Annals of surgery
represented evidence source
institution
Hepatology (Baltimore, Md.)
represented evidence source
institution
Journal of the American Society of Nephrology : JASN
represented evidence source
institution
Clinical journal of the American Society of Nephrology : CJASN
represented evidence source
institution
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
represented evidence source
institution
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
represented evidence source
Claim: Not linked · Evidence: f345f4992b2f14add665d71883e48092
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Claim: Not linked · Evidence: 8fefbdefc8b818de66af95f30a75310b
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
Claim: Not linked · Evidence: cd77836a339625c7bf92d575b2aefd48
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Claim: Not linked · Evidence: fc28879d16ccb07f3c3186a103f9b340
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.
Claim: Not linked · Evidence: f91bf70443e62f2f348983cc98c20d25
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.
Generated: 9/18/2026, 3:05:20 PM
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
Durable source IDs
6/6
Claim-to-source chain
Partial
Evidence searched through: Not recorded
Last accountable review: Not recorded
Inspect unresolved signals (4)
No governed reviewed scientific source is represented.
The last accountable evidence-review date is not recorded.
At least one claim-to-original-source traceability step is not represented.
The literature search-through date is not recorded.
These are documentary and scientific-review signals, not conclusions of harm, ineffectiveness, safety, or absence of research.
Human relevance0
Study design0
Evidence breadth0
Consistency0
Governance quality0
Uncertainty resolution0
Why this rating
No governed reviewed scientific evidence is available.
Source-level review states (6)
identifiedother
[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
This maturity index describes evidence-base development and governance. It is not a probability of efficacy, safety, truth, medical advice, or regulatory approval. Read the methodology.